PDF(Pubmed)
Abstract：
BACKGROUND: There are no clinical practice guidelines addressing the treatment of tobacco-cannabis co-use and a dearth of studies to inform treatment for co-use. This narrative review aims to (1) summarize promising intervention components used in published co-use treatment studies, (2) describe key gaps and emerging issues in co-use, and (3) provide recommendations and considerations in the development and evaluation of co-use interventions.
METHODS: We conducted a literature search in June 2024 across several databases to update previous reviews on tobacco-cannabis co-use treatment. We found 9 published intervention studies that specifically addressed treatment for both substances. Data from these studies were manually extracted and summarized.
RESULTS: Most of the 9 included studies (1) focused on acceptability and/or feasibility, (2) provided both psychosocial/behavioral and pharmacotherapy intervention components, (3) were conducted in adults, and (4) were delivered in-person, with some having digital asynchronous components, for a 5-to-12-week duration. The most common psychosocial/behavioral strategies used were Cognitive Behavioral Therapy, Motivational Interviewing, and Contingency Management; while the most common pharmacotherapy was Nicotine Replacement Therapy. There was no evidence of compensatory use of tobacco or cannabis when providing simultaneous treatment for both substances.
CONCLUSIONS: The literature to date provides support for well-integrated multi-component interventions of psychosocial/behavioral and pharmacotherapy strategies for co-use treatment. This review reinforces an urgent need for treatments targeting tobacco and cannabis co-use. Future interventions should address key gaps, including co-use of vaporized products among youth and young adults, tailored interventions for priority populations, and digital applications to increase reach and advance health equity.
METHODS: We conducted a literature search in June 2024 across several databases to update previous reviews on tobacco-cannabis co-use treatment. We found 9 published intervention studies that specifically addressed treatment for both substances. Data from these studies were manually extracted and summarized.
RESULTS: Most of the 9 included studies (1) focused on acceptability and/or feasibility, (2) provided both psychosocial/behavioral and pharmacotherapy intervention components, (3) were conducted in adults, and (4) were delivered in-person, with some having digital asynchronous components, for a 5-to-12-week duration. The most common psychosocial/behavioral strategies used were Cognitive Behavioral Therapy, Motivational Interviewing, and Contingency Management; while the most common pharmacotherapy was Nicotine Replacement Therapy. There was no evidence of compensatory use of tobacco or cannabis when providing simultaneous treatment for both substances.
CONCLUSIONS: The literature to date provides support for well-integrated multi-component interventions of psychosocial/behavioral and pharmacotherapy strategies for co-use treatment. This review reinforces an urgent need for treatments targeting tobacco and cannabis co-use. Future interventions should address key gaps, including co-use of vaporized products among youth and young adults, tailored interventions for priority populations, and digital applications to increase reach and advance health equity.
摘要：
背景：没有关于烟草-大麻共同使用的治疗的临床实践指南，并且缺乏为共同使用提供治疗信息的研究。这篇叙述性综述旨在(1)总结已发表的共同使用治疗研究中使用的有希望的干预成分，(2)描述共同使用中的关键差距和新出现的问题，（3）在开发和评估共同使用干预措施时提供建议和考虑因素。
方法：我们在2024年6月对几个数据库进行了文献检索，以更新以前关于烟草-大麻共同使用治疗的综述。我们发现了9项已发表的干预研究，专门针对这两种物质的治疗。来自这些研究的数据是手动提取和总结的。
结果：9项纳入的研究（1）大部分集中在可接受性和/或可行性，(2)提供心理社会/行为和药物治疗干预组件，（3）在成人中进行，和（4）亲自交付，其中一些具有数字异步组件，持续5到12周。最常见的社会心理/行为策略是认知行为疗法，激励式面试,和应急管理；而最常见的药物治疗是尼古丁替代疗法。在同时治疗两种物质时，没有证据表明补偿性使用烟草或大麻。
结论：迄今为止的文献为共同使用治疗的心理社会/行为和药物治疗策略的良好整合的多成分干预提供了支持。这项审查加强了对针对烟草和大麻共同使用的治疗的迫切需要。未来的干预措施应解决关键差距，包括年轻人和年轻人共同使用蒸发产品，为优先人群量身定制的干预措施，和数字应用，以增加覆盖面和促进健康公平。
方法：我们在2024年6月对几个数据库进行了文献检索，以更新以前关于烟草-大麻共同使用治疗的综述。我们发现了9项已发表的干预研究，专门针对这两种物质的治疗。来自这些研究的数据是手动提取和总结的。
结果：9项纳入的研究（1）大部分集中在可接受性和/或可行性，(2)提供心理社会/行为和药物治疗干预组件，（3）在成人中进行，和（4）亲自交付，其中一些具有数字异步组件，持续5到12周。最常见的社会心理/行为策略是认知行为疗法，激励式面试,和应急管理；而最常见的药物治疗是尼古丁替代疗法。在同时治疗两种物质时，没有证据表明补偿性使用烟草或大麻。
结论：迄今为止的文献为共同使用治疗的心理社会/行为和药物治疗策略的良好整合的多成分干预提供了支持。这项审查加强了对针对烟草和大麻共同使用的治疗的迫切需要。未来的干预措施应解决关键差距，包括年轻人和年轻人共同使用蒸发产品，为优先人群量身定制的干预措施，和数字应用，以增加覆盖面和促进健康公平。
